{
    "clinical_study": {
        "@rank": "62210", 
        "arm_group": [
            {
                "arm_group_label": "LY2835219 + Pemetrexed", 
                "arm_group_type": "Experimental", 
                "description": "LY2835219 given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 500 milligrams/square meter (mg/m^2) pemetrexed given intravenously over approximately 10 minutes on Day 1 of a 21-day cycle.  Participants may continue to receive treatment until discontinuation criteria are met."
            }, 
            {
                "arm_group_label": "LY2835219 + Gemcitabine", 
                "arm_group_type": "Experimental", 
                "description": "LY2835219 given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 1250 milligram/square meter (mg/m^2) gemcitabine given intravenously over approximately 30 minutes on Days 1 and 8 of a 21-day cycle.  Participants may continue to receive treatment until discontinuation criteria are met."
            }, 
            {
                "arm_group_label": "LY2835219 + Ramucirumab", 
                "arm_group_type": "Experimental", 
                "description": "LY2835219 given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Day 1 of a 21-day cycle.  Participants may continue to receive treatment until discontinuation criteria are met."
            }, 
            {
                "arm_group_label": "LY2835219 + Trametinib", 
                "arm_group_type": "Experimental", 
                "description": "LY2835219 given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 2 mg trametinib given orally every 24 hours on Days 1 through 21 of a 21-day cycle.  Participants may continue to receive treatment until discontinuation criteria are met."
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to evaluate the safety of the study drug known as\n      LY2835219 in combination with another anti-cancer drug in participants with NSCLC that is\n      advanced or has spread to other parts of the body (stage IV). The study will also\n      investigate how the body processes the combination treatment and how the study drug affects\n      the body. The study will also collect disease-related symptoms and participant-reported pain\n      related to NSCLC."
        }, 
        "brief_title": "A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma, Non-small Cell Lung", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  For all Parts:  The participant must have stage IV non-small cell lung cancer\n             (NSCLC).\n\n          -  For Part A (LY2835219 + Pemetrexed):  Non-squamous subtypes only.  The participant\n             must have received at least one but no more than three prior therapies for NSCLC.\n\n          -  For Part B (LY2835219 + Gemcitabine):  Any subtype.  The participant must have\n             received at least two but not more than three prior therapies for NSCLC.\n\n          -  For Part C (LY2835219 + Ramucirumab):  Any subtype.  The participant must have\n             received at least two but not more than three prior therapies for NSCLC.\n\n          -  For Part D (LY2835219 + Trametinib):  Any subtype.  The participant must not have\n             received more than three prior therapies for NSCLC. The participant must not have\n             received prior treatment with a mitogen-activated protein kinase (MEK) inhibitor.\n\n          -  Have either measureable or nonmeasurable disease as defined by the Response\n             Evaluation Criteria in Solid Tumors.\n\n          -  Have adequate organ function including:\n\n               -  Hematologic:  Absolute neutrophil count (ANC) 1.5 x 109/liter (L), platelets 100\n                  x 109/L, and hemoglobin 8 gram/deciliter (g/dL)\n\n               -  Hepatic:  Bilirubin 1.5 times upper limits of normal (ULN), alanine\n                  aminotransferase (ALT) and aspartate transaminase (AST) 3.0 times ULN. For\n                  participants with tumor involvement of the liver, AST and ALT equaling \u22645.0\n                  times ULN are acceptable. Alkaline phosphatase \u22645.0 times ULN for participants\n                  with tumor involvement of the bone is acceptable.\n\n               -  Renal:  Serum creatinine 1.5 times ULN.\n\n          -  Have a performance status \u22641 on the Eastern Cooperative Oncology Group (ECOG) scale.\n\n          -  Have discontinued all previous therapies for cancer (including chemotherapy,\n             radiotherapy, immunotherapy, and investigational therapy) for at least 21 days for\n             myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving\n             study drug, and recovered from the acute effects of therapy (treatment related\n             toxicity resolved to baseline) except for residual alopecia.\n\n          -  Have an estimated life expectancy of \u226512 weeks.\n\n          -  Are able to swallow oral medications.\n\n        Exclusion Criteria:\n\n          -  Have a personal history of any of the following conditions:  presyncope or syncope of\n             either unexplained or cardiovascular etiology, ventricular arrhythmia (including but\n             not limited to ventricular tachycardia and ventricular fibrillation), or sudden\n             cardiac arrest.  Exception:  Participants with controlled atrial fibrillation for >30\n             days prior to study treatment are eligible.\n\n          -  Have central nervous system (CNS) metastasis with development of associated\n             neurological changes 14 days prior to receiving study drug.  Participants may be\n             receiving a stable dose of corticosteroids.\n\n          -  Have a history of any other cancer (except non-melanoma skin cancer or carcinoma\n             in-situ of the cervix), unless in complete remission with no therapy for a minimum of\n             3 years.\n\n          -  Females who are pregnant or lactating.\n\n          -  Have active bacterial, fungal, and/or known viral infection (for example, human\n             immunodeficiency virus [HIV] antibodies, hepatitis B surface antigen [HBSAg], or\n             hepatitis C antibodies).  Screening is not required for enrollment.\n\n          -  Have QTc interval of > 470 millisecond (msec) on screening electrocardiogram (ECG).\n\n        Additional Exclusion Criteria For Part C\n\n        -History or evidence of cardiovascular risk including any of the following:\n\n          -  History of acute coronary syndromes (including myocardial infarction and angina),\n             coronary angioplasty, or stenting within 6 months prior to enrollment.\n\n          -  History or evidence of current \u2265Class II congestive heart failure as defined by New\n             York Heart Association.\n\n          -  Treatment refractory hypertension defined as a blood pressure of systolic >140\n             millimeter of mercury (mmHg) and/or diastolic >90 mmHg which cannot be controlled by\n             antihypertensive therapy.\n\n          -  Participants with intracardiac defibrillators.\n\n        Additional Exclusion Criteria For Part D\n\n          -  History of interstitial lung disease.\n\n          -  History or evidence of cardiovascular risk including any of the following\n\n               -  History of acute coronary syndromes (including myocardial infarction and\n                  angina), coronary angioplasty, or stenting within 6 months prior to enrollment.\n\n               -  Treatment refractory hypertension defined as a blood pressure of systolic >140\n                  mmHg and/or diastolic >90 mmHg which cannot be controlled by anti-hypertensive\n                  therapy.\n\n               -  Participants with intra-cardiac defibrillators or permanent pacemakers.\n\n          -  History or current evidence/risk of retinal vein occlusion (RVO) or central serous\n             retinopathy:\n\n               -  Ophthalmologic exam is required at screening.  Safety monitoring to assess for\n                  visual changes will be required throughout the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "99", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079636", 
            "org_study_id": "15266", 
            "secondary_id": "I3Y-MC-JPBJ"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LY2835219 + Pemetrexed", 
                    "LY2835219 + Gemcitabine", 
                    "LY2835219 + Ramucirumab", 
                    "LY2835219 + Trametinib"
                ], 
                "description": "Administered orally", 
                "intervention_name": "LY2835219", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LY2835219 + Pemetrexed", 
                "description": "Administered IV", 
                "intervention_name": "Pemetrexed", 
                "intervention_type": "Drug", 
                "other_name": "Alimta"
            }, 
            {
                "arm_group_label": "LY2835219 + Gemcitabine", 
                "description": "Administered IV", 
                "intervention_name": "Gemcitabine", 
                "intervention_type": "Drug", 
                "other_name": "Gemzar"
            }, 
            {
                "arm_group_label": "LY2835219 + Ramucirumab", 
                "description": "Administered IV", 
                "intervention_name": "Ramucirumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LY2835219 + Trametinib", 
                "description": "Administered orally", 
                "intervention_name": "Trametinib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Pemetrexed"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Fayetteville", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72703"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87106"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28204"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38120"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28034"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Majadahonda", 
                        "country": "Spain", 
                        "zip": "28222"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain", 
                        "zip": "41013"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Spain"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with One or More Drug Related Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline through study completion (15 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079636"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of LY2835219, Pemetrexed, Gemcitabine, Ramucirumab, and Trametinib", 
                "safety_issue": "No", 
                "time_frame": "Baseline through study completion (15 months)"
            }, 
            {
                "measure": "Number of Participants with a Complete or Partial Tumor Response (Overall Response Rate)", 
                "safety_issue": "No", 
                "time_frame": "Baseline through study completion (15 months)"
            }, 
            {
                "measure": "Progression Free Survival Time", 
                "safety_issue": "No", 
                "time_frame": "Date of first dose until first documented progression or death (15 months)"
            }, 
            {
                "measure": "Change from Baseline in MD Anderson Symptom Inventory Scale-Lung Cancer (MDASI-LC)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Cycle 3 (cycle = 21 days)"
            }, 
            {
                "measure": "Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2835219, Pemetrexed, Gemcitabine, Ramucirumab, and Trametinib", 
                "safety_issue": "No", 
                "time_frame": "Baseline through study completion (15 months)"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}